OncoCube (Delaware, US) was founded by Erden Banoglu, Burcu Çalışkan and Özgür Şahin with the aim of bringing our proprietary anticancer small molecules to the market.

 

As a significant step forward, TACC3 inhibitors developed in our labs at Gazi and Bilkent Universities were included in the company pipeline. The company has shown proof-of-principle with a small molecule TACC3 inhibitor that has potent anticancer activity in multiple tumor xenograft animal models. OncoCube recently signed a Collaborative Research Agreement with the option to license with a U.S. based drug development company to further develop these TACC3 inhibitors for human clinical studies! Ongoing optimization efforts aim to generate bioavailable TACC3 inhibitors with improved tumor-specificity and pharmacokinetic profiles. OncoCube Therapeutics plans to select their clinicalcandidate for beginning the Investigational New Drug (IND) process in 2021.

​